| Can we personalize treatment for kidney diseases? | |
| | |
MedLine Citation:
|
PMID: 19808246 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The idea of individualizing therapies to obtain optimal clinical results is not new but has only recently been applied to kidney diseases. Nonetheless, kidney disorders present a variety of opportunities to personalize medicine. Here, the heterogeneity of kidney disorders is reviewed to provide a rationale for pursuing personalized medicine. Data on adjusting therapy on the basis of pharmacogenetics/genomics and pharmacodynamics are summarized to demonstrate where the field is, and biomarker studies that reflect the future of personalized medicine are discussed. The goal of this review is to demonstrate that we can personalize therapy for kidney diseases but that considerable investment in new research will be required for personalized medicine to be routinely used in nephrology clinics. |
| | |
Authors:
|
Brad H Rovin; Alison M McKinley; Daniel J Birmingham |
Related Documents
:
|
19417116 - Personalized medicine: reality and reality checks. 16548306 - Closing mandibular first molar spaces in adults. 17659116 - Confined-space accidents on the farm: the manure pit and the silo. 20695246 - Is it time for a new practice environment? part ii: an operational approach to determin... 20101766 - Colonoscopic perforation: incidence, risk factors, management and outcome. 16504896 - Current management of enterocutaneous fistula. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review Date: 2009-09-17 |
Journal Detail:
|
Title: Clinical journal of the American Society of Nephrology : CJASN Volume: 4 ISSN: 1555-905X ISO Abbreviation: - Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-10-07 Completed Date: 2010-01-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101271570 Medline TA: Clin J Am Soc Nephrol Country: United States |
Other Details:
|
Languages: eng Pagination: 1670-6 Citation Subset: IM |
Affiliation:
|
Division of Nephrology, Department of Internal Medicine, Ohio State University College of Medicine, Columbus 43210, OH 43210, USA. rovin.1@osu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aryl Hydrocarbon Hydroxylases
/
genetics Azathioprine / therapeutic use Calcineurin / antagonists & inhibitors Complement C3 / analysis Complement C4 / analysis Cyclophosphamide / therapeutic use Humans Individualized Medicine* Kidney Diseases / drug therapy*, immunology Leukocytes, Mononuclear / drug effects Lupus Nephritis / drug therapy Mycophenolic Acid / analogs & derivatives, therapeutic use Peptidyl-Dipeptidase A / genetics Receptors, Fc / genetics |
| Grant Support | |
ID/Acronym/Agency:
|
R01DK074661/DK/NIDDK NIH HHS; R21DK077331/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Complement C3; 0/Complement C4; 0/Receptors, Fc; 128794-94-5/mycophenolate mofetil; 24280-93-1/Mycophenolic Acid; 446-86-6/Azathioprine; 50-18-0/Cyclophosphamide; EC 1.14.14.1/Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1/CYP2C19 protein, human; EC 3.1.3.16/Calcineurin; EC 3.4.15.1/Peptidyl-Dipeptidase A |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study.
Next Document: Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus format...